India Pharma Outlook Team | Friday, 15 April 2022
Britain's medicines regulator on Thursday permitted the use of Moderna's COVID-19 vaccine in children between six and 11 years, as the country bolsters itself for fighting coronavirus infections amid the spread of new virus variants. The Medicines and Healthcare products Regulatory Agency said it approves the moderna covid 19 vaccine spikevax for use in 6 to 11 year olds the approval was granted after Moderna's vaccine, known as Spikevax, met the required standards of safety, quality and effectiveness.
While most children grow mild or no symptoms with COVID-19, they could still spread the virus and some remain at risk of becoming seriously ill as new, highly contagious variants such as Omicron and its sub-variants are driving up cases. A Reuters tally pharmaceuticals worldwide covid cases
surpass 500 mln omicron variant ba2 surges 2022-04-14 showed worldwide cases surpassed 500 million. However, official data on Thursday showed that COVID-19 prevalence in England fell to 1 in 14 people in the week ending April 9, compared with a record high of 1 in 13 recorded in the previous two weeks. Spikevax was already approved in Britain for those over 12 years, and the extension to include younger children comes hours after the regulator approved French company Valneva's easy-to-store COVID-19 vaccine for adults up to 50 years of age.
MHRA chief June Raine said in a declaration it would be up to Britain's Joint Committee on Vaccination and Immunisation to advise on whether Moderna's vaccine will be offered to the younger group as part of the country's immunisation programme. Moderna last year said its two-dose vaccine, based on messenger RNA (mRNA) technology, generated virus-neutralizing antibodies in children aged six to 11 years and safety was comparable to that seen in trials of adolescents and adults.
Last month, the U.S.-based drugmaker said it would seek authorisation of Spikevax in children younger than 6 years old based on data showing it generated a similar immune response to adults in Moderna's clinical trial when Omicron was predominant.
, CDSCO.jpg)
